Karlin Daniel 4

What Happened Daniel Karlin, Chief Medical Officer of Definium Therapeutics (DFTX), received an award of 150,000 restricted stock units (RSUs) reported on Feb 3, 2026. The Form 4 lists the acquisition price as $0.00 (award/grant). These RSUs are a contingent right to receive common shares if vesting conditions are met; this is an award, not a market purchase or sale.

Key Details

• Transaction date: 2026-02-03; Filing date: 2026-02-05 (Form 4 accession 0001193125-26-039576).
• Amount: 150,000 RSUs; reported acquisition price $0.00.
• Vesting: 16 equal quarterly installments beginning June 1, 2026, subject to continuous service on each vesting date (footnote F1).
• Shares owned after the transaction: not specified in the provided filing details.
• No indication of a 10b5-1 plan, tax withholding, or late filing in the supplied information.

Context RSUs are common executive compensation that do not require an upfront cash outlay and only convert to actual shares if/when they vest. Because these units vest over time and are subject to continued service, they do not represent immediately tradable shares and do not by themselves signal an immediate change in insider sentiment. Any future sales or conversions at vesting would be reported separately.